Clinical Trials
53 trialsPanitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
ABACO
University of Campania Luigi Vanvitelli
Liver Transplantation and Metastatic Colo-rectal Cancer.
Oslo University Hospital
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study
University of Kansas Medical Center
IPOS
Zealand University Hospital
CETIDYL
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Shanghai Zhongshan Hospital
NeoFox
WntResearch AB
FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage
ChineseAMS
CIFOXRC
Tongji Hospital
To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
Fujian Cancer Hospital
Intravenous Iron Infusion on Chemotherapy-induced Anemia
Korea University Guro Hospital
Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer
China Medical University, China
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
National Guard Health Affairs
SGM-CLM
Leiden University Medical Center
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial
Sheba Medical Center
A Novel Technique of HALS With CME and CVL for RCC
West China Hospital
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
Fudan University
RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
ECKINOXE
Assistance Publique - Hôpitaux de Paris
A Phase â…¡ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients
Fudan University
ANGIOSWITCH
Grupo Hospital de Madrid
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Cancer Institute (NCI)
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
CIKCC
Guangdong Provincial Hospital of Traditional Chinese Medicine
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer
Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer
National Cancer Institute (NCI)
A Study With Health Educational Material on Health Promotion in Cancer Survivors
National Cancer Center, Korea
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)
UFUR
National Cheng-Kung University Hospital
Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer
National Cancer Institute (NCI)
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)